Transglutaminase inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 26, Issue 1, 2016, Pages 49-63

  Keillor, Jeffrey W ^a   Apperley, Kim Y P ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cancer; Celiac disease; Factor XIII; Fibrosis; Huntington's disease; Inhibitors; TG2; Transglutaminase

Indexed keywords

ENZYME INHIBITOR; TRANSGLUTAMINASE INHIBITOR; UNCLASSIFIED DRUG; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

AMINO ACID SEQUENCE; CANCER CELL LINE; CELIAC DISEASE; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CHEMICAL REACTION; CONFORMATIONAL TRANSITION; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUNTINGTON CHOREA; IC50; IMMUNE RESPONSE; IN VITRO STUDY; PHARMACOPHORE; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN CROSS LINKING; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DESIGN; ENZYMOLOGY; HUNTINGTON DISEASE; METABOLISM; NEOPLASMS; PATENT;

ANIMALS; CELIAC DISEASE; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; HUNTINGTON DISEASE; NEOPLASMS; PATENTS AS TOPIC; TRANSGLUTAMINASES;

EID: 84955671362     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2016.1115836     Document Type: Review

References (117)

1. Keillor JW, Clouthier CM, Apperley KYP, et al. Acyl transfer mechanisms of tissue transglutaminase. Bioorg Chem. 2014;57:186-197.
2. Pietsch M, Wodtke R, Pietzsch J, et al. Tissue transglutaminase: An emerging target for therapy and imaging. Bioorg Med Chem Lett. 2013;23(24):6528-6543.
3. Nurminskaya MV, Belkin AM. Cellular functions of tissue transglutaminase. Int Rev Cell Mol Biol. 2012;294:1-97.
4. Siegel M, Strnad P, Watts RE, et al. Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury. PLoS One. 2008;3(3): e1861.
5. Ariens RAS, Lai T-S, Weisel JW, et al. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood. 2002;100(3):743-754.
6. Gundemir S, Colak G, Tucholski J, et al. Transglutaminase 2: A molecular Swiss army knife. Biochim Biophys Acta Mol Cell Res. 2012;1823(2):406-419.
7. Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. Biochem J. 2002;368(2):377-396.
8. Fesus L, Piacentini M. Transglutaminase 2: An enigmatic enzyme with diverse functions. Trends Biochem Sci. 2002;27 (10):534-539.
9. Balajthy Z, Csomos K, Vamosi G, et al. Tissue-transglutaminase contributes to neutrophil granulocyte differentiation and functions. Blood. 2006;108(6):2045-2054.
10. Melino G, Annicchiarico-Petruzzelli M, Piredda L, et al. Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells. Mol Cell Biol. 1994;14(10):6584-6596.
11. Di Venere A, Rossi A, De Matteis F, et al. Opposite effects of Ca2+ and GTP binding on tissue transglutaminase tertiary structure. J Biol Chem. 2000;275(6):3915-3921.
12. Pinkas DM, Strop P, Brunger AT, et al. Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol. 2007;5(12):2788-2796.
13. Liu S, Cerione RA, Clardy J. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc Natl Acad Sci USA. 2002;99(5):2743-2747.
14. Stamnaes J, Pinkas DM, Fleckenstein B, et al. Redox regulation of transglutaminase 2 activity. J Biol Chem. 2010;285 (33):25402-25409.
15. Keillor JW, Apperley KYP, Akbar A. Inhibitors of tissue transglutaminase. Trends Pharmacol Sci. 2015;36(1):32-40.
16. Caccamo D, Curro M, Ientile R. Potential of transglutaminase 2 as a therapeutic target. Expert Opin Ther Targets. 2010;14 (9):989-1003.
17. Iismaa SE, Mearns BM, Lorand L, et al. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev. 2009;89(3):991-1023.
18. Olsen KC, Sapinoro RE, Kottmann RM, et al. Transglutaminase 2 and its role in pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(6):699-707.
19. Prime ME, Andersen OA, Barker JJ, et al. Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for huntington's disease. J Med Chem. 2012;55(3):1021-1046.
20. Fleckenstein B, Molberg O, Qiao S-W, et al. Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation reactions. J Biol Chem. 2002;277 (37):34109-34116.
21. Kumar S, Donti TR, Agnihotri N, et al. Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways. Int J Cancer. 2014;134 (12):2798-2807.
22. Badarau E, Collighan RJ, Griffin M. Recent advances in the development of tissue transglutaminase (TG2) inhibitors. Amino Acids. 2013;44(1):119-127.
23. Keillor JW, Chabot N, Roy I, et al. Irreversible inhibitors of tissue transglutaminase. Adv Enzymol Relat Areas Mol Biol. 2011;78:415-447.
24. Siegel M, Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther. 2007;115 (2):232-245.
25. Wodzinska JM. Transglutaminases as targets for pharmacological inhibition. Mini-Rev Med Chem. 2005;5(3):279-292.
26. Leblanc A, Gravel C, Labelle J, et al. Kinetic studies of guinea pig liver transglutaminase reveal a general-base-catalyzed deacylation mechanism. Biochemistry. 2001;40(28):8335-8342.
27. Gnaccarini C, Ben-Tahar W, Mulani A, et al. Site-specific protein propargylation using tissue transglutaminase. Org Biomol Chem. 2012;10(27):5258-5265.
28. Case A, Stein RL. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor. Biochemistry. 2007;46(4):1106-1115.
29. Griffith OW, Larsson A, Meister A. Inhibition of-glutamylcysteine synthetase by cystamine: An approach to a therapy of 5-oxoprolinuria (pyroglutamic aciduria). Biochem Biophys Res Commun. 1977;79(3):919-925.
30. Besouw M, Masereeuw R, van den Heuvel L, et al. Cysteamine: An old drug with new potential. Drug Discov Today. 2013;18 (15-16):785-792.
31. Robertson JG. Mechanistic basis of enzyme-targeted drugs. Biochemistry. 2005;44(15):5561-5571.
32. Stachulski AV, Baillie TA, Park BK, et al. The generation, detection, and effects of reactive drug metabolites. Med Res Rev. 2013;33(5):985-1080.
33. Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug. Press release. Darmstadt, Germany: Zedira, 2015. [cited 2015 Sept 2]. Available from: http://zedira. com/News/Press-Release-Dr-Falk-Pharma-and-Zedira-enter-phase-Iclinical-trials-for-a-celiac-disease-drug-71.
34. Syntex, Inc. 3, 5-Substituted 4, 5-dihydroisoxazoles as transglutaminase inhibitors. US4912120. 1990.
35. Syntex, Inc. Transglutaminase inhibitors. US4929630. 1990.
36. Syntex, Inc. Transglutaminase inhibitors. US4970297. 1990.
37. Merck & Co., Inc. Certain imidazole compounds as transglutaminase inhibitors. US4968713. 1990.
38. Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors. US5019572. 1991.
39. Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors. US5021440. 1991.
40. Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors. US5030644. 1991.
41. Merck & Co., Inc. Triazole compounds and their use as transglutaminase inhibitors. US5047416. 1991.
42. Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors. US5084444. 1992.
43. Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors. US5098707. 1992.
44. Merck & Co., Inc. Methods for thrombolytic therapy. US5188830. 1993.
45. Curtis CG, Lorand L. Fibrin-stabilizing factor (factor XIII). Methods Enzymol. 1976;45(Proteolytic Enzymes, Pt. B):177-191.
46. University of Texas. Growth arrest of proliferating cells by transglutaminase inhibitors. WO9108739. 1991.
47. University of Texas. Effect of transglutaminase inhibition on microfilariae development and macrofilariae viability. US5124358. 1992.
48. Medicis Corp. Transglutaminase enzyme inhibitors. WO9213530. 1992.
49. Folk JE, Chung SI. Transglutaminases. Methods Enzymol. 1985;113(Glutamate, Glutamine, Glutathione, Relat. Compd.):358-375.
50. Raggio-Italgene SPA. Peptide effective as substrate and/or inhibitor of the transglutaminase enzyme and use thereof for diagnostics and therapeutics. IT1264084. 1996.
51. Biopharm Research & Development. Inhibitors of fibrin cross-linking and/or transglutaminases. US6025330. 2000.
52. Slaughter TF, Achyuthan KE, Lai TS, et al. A microtiter plate transglutaminase assay utilizing 5-(biotinamido)pentylamine as substrate. Anal Biochem. 1992;205 (1):166-171.
53. N Zyme Biotech GmbH. Inhibitors of transglutaminase. US2002132776; 2002.
54. Grossowicz N, Wainfan E, Borek E, et al. Enzymic formation of hydroxamic acids from glutamine and asparagine. J Biol Chem. 1950;187:111-125.
55. N Zyme Biotech GmbH. Control of transglutaminase catalyzed protein modification by selective irreversible transglutaminase inhibitors. EP1602719. 2005.
56. Lorand L, Lockridge OM, Campbell LK, et al. Transamidating enzymes. II. Continuous fluorescent method suited for automating measurements of Factor XIII in plasma. Anal Biochem. 1971;44 (1):221-231.
57. Apotex Inc. Sulfonamide derivatives of 3-substituted imidazol[1, 2-d]-1, 2, 4-thiadiazoles and 3-substituted-[1, 2, 4] thiadiazolo [4, 5-a] benzimidazole as inhibitors of fibrin cross-linking and transglutaminases. US2003225007. 2003.
58. Kitz R, Wilson IB. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem. 1962;237:3245-3249.
59. Brigham and Women's Hospital. Substituted 3, 4-dihydrothieno [2, 3-d] pyrimidines as tissue transglutaminase inhibitors. WO2006060702. 2006.
60. Case A, Stein RL. Kinetic analysis of the action of tissue transglutaminase on peptide and protein substrates. Biochemistry. 2003;42(31):9466-9481.
61. Quark Biotech Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof. WO2006100679; 2006.
62. Alvine Pharmaceuticals, Inc. Transglutaminase inhibitors and methods of use thereof. WO2007050795. 2007.
63. Piper JL, Gray GM, Khosla C. High selectivity of human tissue transglutaminase for immunoactive gliadin peptides: implications for celiac sprue. Biochemistry. 2002;41(1):386-393.
64. Day N, Keillor JW. A continuous spectrophotometric linked enzyme assay for transglutaminase activity. Anal Biochem. 1999;274(1):141-144.
65. National Cancer Center (S. Korea). Glucosamine and derivatives thereof useful as transglutaminase inhibitors. WO2007026996. 2007.
66. Stanford University. Drug therapy for Celiac Sprue. US7265093. 2007.
67. Choi K, Siegel M, Piper JL, et al. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol. 2005;12(4):469-475.
68. Yuan L, Choi K, Khosla C, et al. Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol Cancer Ther. 2005;4 (9):1293-1302.
69. Yuan L, Siegel M, Choi K, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene. 2007;26(18):2563-2573.
70. Stanford University. Transglutaminase inhibitors and methods of use thereof. US7579313. 2009.
71. Aston University. Transglutaminase inhibitors and methods of using the same. EP1648924. 2008.
72. Aston University. Amino acid derivatives and pharmaceutical uses thereof. US7723307. 2010.
73. Huang L, Haylor JL, Hau Z, et al. Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int. 2009;76(4):383-394.
74. Curacyte AG Modified tridegins, production and use thereof as transglutaminase inhibitors. EP1458866. 2008.
75. Fickenscher K, Aab A, Stueber W. A photometric assay for blood coagulation factor XIII. Thromb Haemost. 1991;65 (5):535-540.
76. National Cancer Center (S. Korea). A composition for transglutaminase inhibitor comprising curcumin. KR20100011620. 2010.
77. National Cancer Center (S. Korea). NDGA-containing composition for the suppression of transglutaminase. WO2010011117. 2010.
78. National Cancer Center (S. Korea). A pharmaceutical composition for preventing or treating transglutaminase-related disease comprising sulfarlem, and a method for preventing or treating transglutaminase-related disease by using thereof. KR20100056212. 2010.
79. National Cancer Center (S. Korea). Transglutaminase inhibitor comprising EGCG and a method for producing thereof. US2010144860. 2008.
80. National Cancer Center (S. Korea). Ethacrynic acid for prevention and treatment of transglutaminase-related diseases. WO2010062144. 2010.
81. National Cancer Center (S. Korea). Novel pyrazolodiazepine compounds as a transglutaminase inhibitor, the preparation method thereof and a composition containing the same. WO2010074480. 2010.
82. Numerate, Inc. ; Leland Stanford Junior University. Preparation of 3-acylidene-2-oxindole derivatives for inhibition of transglutaminase 2. WO2012078519. 2012.
83. Gillet SMFG, Pelletier JN, Keillor JW. A direct fluorometric assay for tissue transglutaminase. Anal Biochem. 2005;347 (2):221-226.
84. Klöck C, Jin X, Choi K, et al. Acylideneoxoindoles: A new class of reversible inhibitors of human transglutaminase 2. Bioorg Med Chem Lett. 2011;21(9):2692-2696.
85. Yi MC, Palanski BA, Quintero SA, et al. An unprecedented dual antagonist and agonist of human transglutaminase 2. Bioorg Med Chem Lett. 2015;25 (21):4922-4926.
86. Aston University. Inhibitors of tissue transglutaminase in the treatment and/or prevention of Angiogenic diseases of the eye. WO2012153125. 2012.
87. Griffin M, Mongeot A, Collighan R, et al. Synthesis of potent water-soluble tissue transglutaminase inhibitors. Bioorg Med Chem Lett. 2008;18(20):5559-5562.
88. Aston University. Human tissue transglutaminase peptides or antibodies alter tissue transglutaminase interaction with extracellular matrix, for use in pharmaceuticals and medical implants. WO2012146901. 2012.
89. Wang Z, Collighan RJ, Pytel K, et al. Characterization of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signaling. J Biol Chem. 2012;287 (16):13063-13083.
90. National Cancer Center (S. Korea). Transglutaminase inhibitor containing chlorogenic acid and its preparation method. KR1145930. 2012.
91. National Cancer Center (S. Korea). A pharmaceutical composition for preventing or treating transglutaminase-related disease comprising oltipraz, and a method for preventing or treating transglutaminase-related disease by using thereof. KR101192699. 2012.
92. University of Texas. Methods for treating cancer targeting transglutaminase. US8299040. 2012.
93. Dongguk University Industry-Academic Cooperation Foundation. Method for inhibiting transglutaminase 2 activity using 2-alkyloxy-3-phenylethynyl-4a, 5-dihydropyrido[2, 3-b]pyrazine Derivatives. US2013164813. 2013.
94. Toray Industries, Inc. Tissue transglutaminase inhibitors containing chalcone derivatives (1-thienyl-3-phenyl-2-propen-1-ones) and anti-Alzheimer agents containing them. JP2013180955. 2013.
95. Medical Research Council Technology (U. K.). Anti-human transglutaminase 2 antibodies for diagnosis and treatment of celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurologic diseases and cancer. WO2013175229. 2013.
96. Zedira GmbH. Michael systems as transglutaminase inhibitors. US8471063. 2013.
97. Université de Montréal. Cinnamoyl inhibitors of transglutaminase. US8614233. 2013.
98. Roy I Inhibition réversible et photomarquage de la transglutaminase tissulaire: Université de Montréal. 2014.
99. Dominguez C, Prime M, Marston R, et al. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof. WO2014047288. 2014.
100. Wityak J, Prime ME, Brookfield FA, et al. SAR development of lysine-based irreversible inhibitors of transglutaminase 2 for Huntington's disease. ACS Med Chem Lett. 2012;3(12): 1024-1028.
101. Aston University. Preparation of acylpiperazines as inhibitors of transglutaminase (TGase) and their use in medicine. WO2014057266. 2014.
102. Leland Stanford Junior University. Modulation of tissue transglutaminase activation in disease. US20140322278. 2014.
103. Klöck C, Herrera Z, Albertelli M, et al. Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2. J Med Chem. 2014;57 (21):9042-9064.
104. National Cancer Center (S. Korea). Peptides for inhibiting transglutaminase. US8754033. 2014.
105. University of Texas. TG2 inhibitors and uses thereof. US8765797. 2014.
106. Leland Stanford Junior University. Transglutaminase inhibitors and methods of use thereof. US8871718. 2014.
107. CHDI Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof. US8889716. 2014.
108. Prime ME, Brookfield FA, Courtney SM, et al. Irreversible 4-aminopiperidine transglutaminase 2 inhibitors for Huntington's disease. ACS Med Chem Lett. 2012;3 (9):731-735.
109. Wuhan Xiekang Biotechnology Co., Ltd., Peop. Rep. China. Application of monoclonal antibody against human tissue transglutaminase 2. CN104278013. 2015.
110. Nottingham Trent University. Transglutaminase inhibitor peptides and therapeutic uses thereof treatment of degenerative diseases. WO2015055998. 2015.
111. Japan Science and Technology Agency. Inhibitor of protein crosslinking and use of the same. US8937091. 2015.
112. Ozaki S, Ebisui E, Hamada K, et al. Potent transglutaminase inhibitors, aryl-aminoethyl ketones. Bioorg Med Chem Lett. 2010;20(3):1141-1144.
113. CHDI Foundation, Inc. Transglutaminse TG2 inhibitors, pharmaceutical compositions, and methods of use thereof. US8946197; 2015.
114. Zedira GmbH. Pyridinone derivatives as tissue transglutaminase inhibitors. EP2797892. 2015.
115. Zedira GmbH. Pyridinone derivatives as tissue transglutaminase inhibitors. WO2014012858. 2014.
116. Lindemann I, Boettcher J, Oertel K, et al. Inhibitors of Transglutaminase 2: A Therapeutic Option in Celiac Disease. 2012, PDB ID: 3S3S
117. Folk JE, Cole PW. Structural requirements of specific substrates for guinea pig liver transglutaminase. J Biol Chem. 1965;240 (7):2951-2960.